Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy Presented ByProf. Eric Van Cutsem, KU Leuven, Belgium TrialPhase 2, TASCO1 ConferenceASCO GI 2021 12 March, 2021 11:35